All articles by Mrinmoyee Hazarika
Mrinmoyee Hazarika
Novartis makes offer to acquire French CDMO CellforCure
Novartis has made an offer to acquire CellforCure, a France-based contract development and manufacturing organisation (CDMO) producing cell and gene therapies in Europe, from LFB for an undisclosed amount.
Research suggests childhood obesity major risk factor for hip disease
New research has revealed that childhood obesity is causing growing number of adolescents to develop the Slipped Capital Femoral Epiphysis (SCFE) hip disease requiring immediate surgery.
Enesi Pharma and WRAIR to develop vaccine for Shigella infection
Enesi Pharma has signed a cooperative research and development agreement (CRADA) with the US Department of Defense Laboratory unit Walter Reed Army Institute of Research (WRAIR) to jointly develop a needle-free solid-dose vaccine for the Shigella infection.
AstraZeneca to sell rights to Seroquel to Luye Pharma for $538m
AstraZeneca has signed a deal for the sale and rights to schizophrenia and bipolar disorder treatment Seroquel to Luye Pharma Group for $538m.
US researchers develop new cure for bone diseases
A group of researchers from Washington State University (WSU) has combined natural medical cures with modern biomedical devices develop a treatment for bone injuries and diseases like osteoporosis.
FDA grants breakthrough therapy designation to Fennec’s Pedmark
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Fennec Pharmaceuticals’ Pedmark formulation for cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma (SR-HB).
Daiichi Sankyo and partners to research on new cancer therapy
Daiichi Sankyo, along with Nagoya City University, Chubu University, and Mitsubishi UFJ Capital, is set to begin research on the development of a new cancer hyperthermia therapy.
Arix Bioscience and Fosun partner to develop new clinical therapies
UK-based healthcare and life science company Arix Bioscience has entered a strategic agreement with China’s Fosun International to develop and commercialise new clinical therapies for patients.
Researchers develop new stem-cell based stroke treatment
Researchers from the University of Georgia’s (UGA) Regenerative Bioscience Centre (RBC) in the US, along with UGA’s startup company ArunA Biomedical, have developed a new treatment for stem-cell based stroke treatment that reduces brain damage.
2017: The year’s biggest Pharmaceutical Technology stories
Biogen entered a new agreement with Alkermes to develop and commercialise ALKS 8700 to treat multiple sclerosis (MS), while Australia announced $100m of funding to advance brain cancer research in order to provide a better life to people suffering from the disease. Pharmaceutical-technology.com wraps up the key headlines from 2017.